Medical cannabis for fibromyalgia

Some patients report a reduction in pain intensity, better sleep and more energy in everyday life. A nabilone study included in the 2025 living systematic review showed in 40 participants an improvement on the standard fibromyalgia impact questionnaire compared with a placebo. The individual response varies widely, and careful medical adjustment is a prerequisite.

Options include combination products with THC and CBD, THC-dominant strains and CBD-dominant strains. Combination products are often preferred because pain modulation and tolerability can be balanced well. THC-dominant strains may be considered in the evening when sleep-promoting effects are wanted. CBD-dominant strains are used during the day when a psychoactive effect is to be avoided. The specific choice belongs in the medical consultation.

CBD is not psychoactive and in fibromyalgia is considered in relation to inflammation, tension, tolerability and daytime functioning. Anti-inflammatory and antispasmodic effects are being discussed, and in combination with THC, CBD can improve its tolerability. CBD-dominant strains are therefore often used during the day when a psychoactive effect is to be avoided. Whether CBD alone or in combination with THC may be considered is clarified in the medical consultation.

Both may be considered, depending on the medical assessment. Inhaled cannabis via a vaporiser usually works within a few minutes and lasts two to four hours, while medications taken by mouth, such as oils or capsules, work more slowly, often only after 30 to 90 minutes, but last six to eight hours. In fibromyalgia, combination products with THC and CBD are often preferred because pain modulation and tolerability can be balanced well. Which dosage form and strain suit the individual case is determined in the medical consultation.

Possible side effects are dizziness, a dry mouth, tiredness, mild problems concentrating and a temporarily faster heartbeat. If the THC dose is too high, drowsiness or feelings of anxiety can occur. Patients with fibromyalgia often react particularly sensitively to medication, which is why treatment starts at very low doses. Particular caution is needed with cardiovascular disease, previous mental illness or pregnancy.

Compared with opioids or benzodiazepines, the risk of physical dependence is low. Psychological habituation is possible, above all with permanently high doses of THC. Under medical dose control within a therapeutic framework, this risk falls considerably. Ending therapy should be done gradually and always in consultation with the treating doctor.

In certain cases German statutory health insurers can cover the costs. The prerequisites are a serious illness and evidence that guideline-based therapies such as exercise, pain therapy or psychotherapy have not worked well enough or were not tolerated. In the initial consultation we assess whether an application has a good chance of success in your individual case.

A combination is often possible, because cannabis is meant to complement existing therapies rather than replace them completely. In some cases the need for conventional painkillers can be reduced. Interactions are possible in particular with antidepressants, sedatives and blood thinners. Before any change to therapy, all medicines currently being taken should be discussed openly.

The evidence is still being built up: large multicentre comparative studies are so far lacking, while smaller studies and reviews provide initial indications. A study of the THC analogue nabilone included in the 2025 living systematic review showed in 40 participants an improvement on the standard fibromyalgia impact questionnaire compared with a placebo. Further studies and reviews found indications of reduced pain intensity and improved sleep quality under cannabis therapy, while a recent review still classifies the evidence overall as limited. A final assessment is not yet possible on the basis of current research.